Skip to main content
. 2024 Nov 5;18:313–326. doi: 10.2147/BTT.S489363

Figure 1.

Figure 1

Flow chart of the feasibility and safety of anlotinib plus PD-1 inhibitors for previously treated advanced non-small cell lung cancer.